Curaleaf Holdings, Inc. has announced a significant milestone in its proposed acquisition of Aurora Cannabis. On November 10, 2026, the company confirmed that it has received all required competition law clearances necessary for the deal to proceed. This approval is crucial as it allows Curaleaf to move forward with its plans to acquire 100% of Aurora's voting rights, which is expected to enhance its market position in the cannabis industry.
The acquisition is particularly important for Curaleaf, a leading provider of consumer and medical cannabis products. The clearances were granted by regulatory authorities in Germany and Canada, marking a pivotal step in the acquisition process. Boris Jordan, Chairman and CEO of Curaleaf, expressed optimism about the approval, stating, "With all required competition law clearances secured, the path is clear for Aurora shareholders to realize the value our Offer provides." This sentiment underscores the strategic importance of the acquisition for both companies.
Background
Curaleaf Holdings, Inc. operates within the medicinal chemicals and botanical products sector, classified under SIC code 2833. The company is listed on the OTC market under the ticker CURLF and is recognized as a large accelerated filer. Curaleaf is headquartered in Stamford, Connecticut, and is known for its extensive range of cannabis products and services.
In recent filings, Curaleaf has been active in pursuing growth through acquisitions, with the proposed acquisition of Aurora Cannabis being a key focus. Aurora Cannabis, a competitor in the industry, has been under scrutiny as Curaleaf's offer remains outstanding until December 4, 2026, unless modified or withdrawn.
What the Filing Says
The SEC filing details Curaleaf's receipt of competition law clearances, stating, "On November 10, 2026, Curaleaf Holdings, Inc. issued a statement confirming the company has received all required competition law clearances for the proposed acquisition of Aurora Cannabis." The filing also notes that these approvals were necessary for Curaleaf to complete its acquisition plans.
Impact
This development is likely to impact various stakeholders, including shareholders of both Curaleaf and Aurora Cannabis. With the competition law clearances in place, Curaleaf can enhance its offer to Aurora shareholders, potentially swaying their decisions in favor of the acquisition. Additionally, the successful completion of this acquisition may set a precedent for future mergers and acquisitions within the medicinal chemicals and botanical products industry.
What's Next
The next steps involve the ongoing evaluation of Curaleaf's offer by Aurora's shareholders. The filing does not specify any further actions required from Curaleaf at this time, but the company is expected to continue its engagement with Aurora's board and shareholders as the acquisition deadline approaches.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





